Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 1.092
Filter
1.
BMJ Open ; 11(9), 2021.
Article in English | ProQuest Central | ID: covidwho-1843233

ABSTRACT

ObjectivesKnowledge on the impact of heated tobacco product (HTP) use in pregnant women with associated maternal and neonatal risks for hypertensive disorders of pregnancy (HDP) and low birth weight (LBW) is limited. We aimed to assess the status of HTP use among pregnant women in Japan and explore the association of HTP use with HDP and LBW.DesignCross-sectional study.SettingData from the Japan ‘COVID-19 and Society’ Internet Survey study, a web-based nationwide survey.ParticipantsWe investigated 558 postdelivery and 365 currently pregnant women in October 2020.Primary and secondary outcome measuresInformation on HDP and LBW was collected from the postdelivery women’s Maternal and Child Health Handbooks (maternal and newborn records). We estimated the age-adjusted ORs and 95% CIs of ever HTP smokers for HDP and LBW and compared them with those of never HTP smokers in a logistic regression analysis.ResultsThe prevalence of ever and current HTP use were 11.7% and 2.7% in postdelivery women and 12.6% and 1.1% in currently pregnant women, respectively. Among currently pregnant women who were former combustible cigarette smokers, 4.4% (4/91) were current HTP smokers. Among postdelivery women, ever HTP smokers had a higher HDP incidence (13.8% vs 6.5%, p=0.03;age-adjusted OR=2.48, 95% CI 1.11 to 5.53) and higher LBW incidence (18.5% vs 8.9%, p=0.02;age-adjusted OR=2.36, 95% CI 1.16 to 4.87).ConclusionsIn Japan, the incidence of ever HTP use exceeded 10% among pregnant women, and HTP smoking may be associated with maternal and neonatal risks.

2.
Journal of Integrated Science and Technology ; 10(2):61-66, 2022.
Article in English | Scopus | ID: covidwho-1843221

ABSTRACT

Due to a lack of data on various parameters with COVID-19 in the Indian population, this study was carried out to understand the relation among gender, age and comorbidities in Indian population. The data was collected using a questionnaire-based survey form that included questions on demographic characteristics, infection and any pre-underlying conditions (n=1146). The data showed that the male patients had suffered more from COVID-19 (58.6%). Also, the patients suffering from comorbidity are more likely to suffer from a severe form of COVID-19 and obesity/overweight was identified as the most prevalent (n=69) comorbid condition, followed by diabetes (n=35), thyroid (n=19) and hypertension (n=11). In severe COVID-19 cases, 85% of patients had a comorbid condition. In another study of COVID-19 hospitalized-cases, about 97% of patients were found to have an underlying medical condition. Among these, diabetes (55.9%) was identified as the most prevalent comorbidity. Males and older people are at a higher risk of developing COVID-19 infection in Indian population. The comorbid conditions also predisposed individuals to COVID-19 and aggravated the infection. © 2022. ScienceIN.

3.
BMJ Open ; 11(8), 2021.
Article in English | ProQuest Central | ID: covidwho-1843007

ABSTRACT

ObjectivesTo investigate the combined association of obesity, diabetes mellitus (DM) and cardiovascular disease (CVD) with severe COVID-19 outcomes in adult and elderly inpatients.DesignCross-sectional study based on registry data from Brazil’s influenza surveillance system.SettingPublic and private hospitals across Brazil.ParticipantsEligible population included 21 942 inpatients aged ≥20 years with positive reverse transcription-PCR test for SARS-CoV-2 until 9 June 2020.Main outcome measuresSevere COVID-19 outcomes were non-invasive and invasive mechanical ventilation use, intensive care unit (ICU) admission and death. Multivariate analyses were conducted separately for adults (20–59 years) and elders (≥60 years) to test the combined association of obesity (without and with DM and/or CVD) and degrees of obesity with each outcome.ResultsA sample of 8848 adults and 12 925 elders were included. Among adults, obesity with DM and/or CVD showed higher prevalence of invasive (prevalence ratio 3.76, 95% CI 2.82 to 5.01) and non-invasive mechanical ventilation use (2.06, 1.58 to 2.69), ICU admission (1.60, 1.40 to 1.83) and death (1.79, 1.45 to 2.21) compared with the group without obesity, DM and CVD. In elders, obesity alone (without DM and CVD) had the highest prevalence of ICU admission (1.40, 1.07 to 1.82) and death (1.67, 1.00 to 2.80). In both age groups, obesity alone and combined with DM and/or CVD showed higher prevalence in all outcomes than DM and/or CVD. A dose–response association was observed between obesity and death in adults: class I 1.32 (1.05 to 1.66), class II 1.41 (1.06 to 1.87) and class III 1.77 (1.35 to 2.33).ConclusionsThe combined association of obesity, diabetes and/or CVD with severe COVID-19 outcomes may be stronger in adults than in elders. Obesity alone and combined with DM and/or CVD had more impact on the risk of COVID-19 severity than DM and/or CVD in both age groups. The study also supports an independent relationship of obesity with severe outcomes, including a dose–response association between degrees of obesity and death in adults.

4.
Journal of Clinical Medicine ; 11(9):2435, 2022.
Article in English | ProQuest Central | ID: covidwho-1842885

ABSTRACT

Background: The dissemination of recommendations on low-value care alone may not lead to physicians’ behavioral changes. The aim of this study was to evaluate whether a multifaceted behavioral intervention among internal medicine residents could reduce low-value care in hospitalized patients. Methods: A pre–post quality improvement intervention was conducted at the Internal Medicine Division of La Tour hospital (Geneva, Switzerland) from May 2020 to October 2021. The intervention period (3 months) consisted of a multifaceted informational intervention with audits and educative feedback about low-value care. The pre- and post-intervention periods including the same six calendar months were compared in terms of number of blood samples per patient day, prescription rates of benzodiazepines (BZDs) and proton pump inhibitors (PPIs), as well as safety indicators including potentially avoidable readmissions, premature deaths and complications. results: A total of 3400 patients were included in this study;1095 (32.2%) and 1155 (34.0%) were, respectively, hospitalized during the pre- and post-intervention periods. Patient characteristics were comparable between the two periods. Only the number of blood tests per patient day and the BZD prescription rate at discharge were significantly reduced in the post-intervention phase (pre: 0.54 ± 0.43 vs. post: 0.49 ± 0.60, p ≤ 0.001;pre: 4.2% vs. post: 1.7%, p = 0.003, respectively). PPI prescription rates remained comparable. Safety indicators analyses revealed no significant differences between the two periods of interest. Conclusions: Our results demonstrate a modest but statistically significant effect of a multifaceted educative intervention in reducing the number of blood tests and the BZD prescription rate at discharge in hospitalized patients. Limiting low-value services is very challenging and additional long-term interventions are necessary for wider implementation.

5.
African Journal of Microbiology Research ; 16(3):115-120, 2022.
Article in English | CAB Abstracts | ID: covidwho-1841663

ABSTRACT

Oxford AstraZeneca (Covishield) vaccine is the 1st vaccine administered in Bangladesh to prevent the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The antibody response after 1st and 2nd doses of this vaccine was assessed in health care workers of Dhaka Medical College Hospital, Bangladesh. Blood sample was collected from healthcare workers (teachers, clinicians and medical staff) after 28 days of 1st vaccination and 14 days after 2nd vaccination. Quantitative post-vaccination antibody responses were measured using the chemiluminescent immunoassay, ADVIA Centaur (Siemens, Munich, Germany) SARS-CoV-2 IgG (COV2G) assay (output index was 1.00). Vaccine related antibody was found in 126 (41%) participants after 1st dose of AstraZeneca vaccine. After 2nd dose of vaccine, reactive level of antibody was found in 172 (93%) participants. Antibody responses were significantly higher in previously infected participants compared to participants who had no history of previous COVID-19 after 1st dose (51.92+or-50.85 vs 23.67+or-41.07, p=0.001) as well as 2nd dose of vaccine (64.12+or-97.76 vs 35.04+or-64.84, p=0.001). No difference in antibody response was observed among participants with or without comorbidities. Oxford AstraZeneca Covishield vaccine induces a strong immune response after two doses of vaccination.

6.
Embase; 2022.
Preprint in English | EMBASE | ID: ppcovidwho-336229

ABSTRACT

Background: We estimated vaccine effectiveness (VE) of mRNA vaccines among US Veterans during periods of Delta and Omicron variant dominance. Patients included in this study were largely 65 years or older (62,834, 55%), male (101,259, 88%), and non-Hispanic white (66,986, 58%). Methods: We used SARS-CoV-2 laboratory test results to conduct a matched test-negative case-control study to estimate VE of three and two doses of mRNA vaccines against infection (regardless of symptoms), and a matched case-control study to estimate VE against COVID-19related hospitalization and death. We estimated VE as (1- odds ratio) x 100%. Severity of disease was measured using hospital length of stay (LOS) and admission to an intensive care unit (ICU). Results: Against infection, booster doses had 7-times higher VE - 59% (95% confidence interval [CI], 57 to 61) - than 2-dose VE (7%;95% CI, 3 to 10) during the Omicron period. For the Delta period, estimated VE against infection was 90% (95% CI, 88 to 92) among boosted vaccinees, 64% higher than VE among 2-dose vaccinees [55% (95% CI, 51 to 58)]. Against hospitalization, booster dose VE was 87% (95% CI, 80 to 91) during Omicron and 95% (95% CI, 91 to 97) during Delta;the 2-dose VE was 44% (95% CI, 26 to 58) during Omicron and 75% (95% CI, 70 to 80) during Delta. Against death, estimated VE with a booster dose was 94% (95% CI, 85 to 98) during Omicron and 96% (95% CI, 88 to 99) during Delta, while the 2-dose VE was 75% (95% CI, 52 to 87) during Omicron and 93% (95% CI, 85 to 97) during Delta. During the Omicron period, average hospital LOS was 4 days shorter [3 days (95%CI, 3 to 4 days)] than during the Delta period. Conclusions: A mRNA vaccine booster is more effective against infection, hospitalization, and death than 2-dose vaccination among an older male population with comorbidities.

7.
Embase; 2022.
Preprint in English | EMBASE | ID: ppcovidwho-336150

ABSTRACT

Background: Inactivated SARS-CoV-2 vaccine has been included in the national COVID-19 vaccination program in Indonesia since January 2021. The study aims to assess the impacts of inactivated COVID-19 vaccine on infection, hospitalization, and death among adult population aged ≥18 years in Bali, Indonesia. Methods: Test-negative, case control study was conducted by linking SARS-CoV-2 laboratory records, vaccination, and health administrative data for the period of January 13 to June 30, 2021. Case-subjects were defined as individuals who had a positive RT-PCR test for SARSCoV-2 during the period;they were matched with controls (tested negative) (1:1) based on age, sex, district of residence, and week of testing. We estimated the odds of vaccination in PCR confirmed, hospitalization and death due to COVID-19, accounting for the presence of comorbidities and prior infection. Vaccine effectiveness was estimated as (1-odds ratio) x 100%. Results: Total 109,050 RT-PCR test results were retrieved during the January 13 to June 30, 2021. Of these, 14,168 subjects were eligible for inclusion in the study. Total 5518 matched case-control pairs were analyzed. Adjusted vaccine effectiveness (VE) against laboratory-confirmed SARSCoV-2 infection was 14.5% (95% confidence interval -11 to 34.2) at 0-13 days after the first dose;66.7% (95% CI: 58.1- 73.5) at ≥14 days after the second dose. The adjusted effectiveness against hospitalization and COVID-19-associated death was 71.1% (95% CI: 62.9-77.6) and 87.4% (95% CI: 65.1-95.4%) at ≥14 days after receiving the second dose, respectively. Conclusions: Two-dose of inactivated CoronaVac vaccine showed high effectiveness against laboratory confirmed COVID-19 infection, hospitalization, and death associated with COVID-19 among adults aged ≥18 years.

8.
Embase; 2022.
Preprint in English | EMBASE | ID: ppcovidwho-336002

ABSTRACT

Objective: To evaluate the benefits of vaccination on the case fatality rate (CFR) for COVID-19 infections. Design: Multivariate modeling of data from electronic medical records Setting: 130 medical centers of the United States Department of Veterans Affairs Participants: 339,772 patients with COVID-19 confirmed by nucleic acid amplification testing as of September 30, 2021 Methods: The primary outcome was death within 60 days of the diagnosis. Patients were considered vaccinated if they had completed a full series >= 14 days prior to diagnosis. Cases presenting in July - September of 2021 were considered to have the delta variant. Logistic regression was used to derive adjusted odds ratios (OR) for vaccination and infection with delta versus earlier variants. Models were adjusted for demographic traits, standard comorbidity indices, selected clinical terms, and 3 novel parameters representing all prior diagnoses, all prior vital signs/baseline laboratory tests, and current outpatient treatment. Patients with a delta infection were divided into 8 cohorts based upon the time from vaccination to diagnosis (in 4-week blocks). A common model was used to estimate the odds of death associated with vaccination for each cohort relative that of all unvaccinated patients. Results: 9.1% of subjects had been fully vaccinated, and 21.5% were presumed to have the delta variant. 18,120 patients (5.33%) died within 60 days of their diagnoses. The adjusted OR for delta infection was 1.87 +/- 0.05 which corresponds to a relative risk of 1.78. The overall adjusted OR for prior vaccination was 0.280 +/- 0.011 corresponding to a relative risk of 0.291. The study of vaccine cohorts with a delta infection showed that the raw CFR rose steadily after 10-14 weeks. However, the OR for vaccination remained stable for 10-34 weeks. Conclusions: Our study confirms that delta is substantially more lethal than earlier variants and that vaccination is an effective means of preventing COVID death. After adjusting for major selection biases, we found no evidence that the benefits of vaccination on CFR declined over 34 weeks.

9.
PubMed; 2020.
Preprint in English | PubMed | ID: ppcovidwho-335602

ABSTRACT

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and has been a global public health concern. We report coinfection of SARS-CoV-2 and 2009 H1N1 Influenza strain in a French patient with pneumonia leading to acute respiratory distress syndrome. The patient also had a medical history of pulmonary sarcoidosis with a restrictive ventilatory syndrome and obesity, which would be a supplementary risk to develop a poor outcomes. This case highlights the possible coinfection of two severe SARS-CoV-2 and influenza H1N1 viruses in comorbid patient, which presents a higher risk to extend the care duration. The overlapping clinical features of the two respiratory syndromes is a challenge, and awareness is required to recommend an early differential diagnosis and it's necessary to adopt the vigilant preventive measures and therapeutic strategies to prevent a deleterious impacts in patients with comorbid factors.

10.
Embase; 2022.
Preprint in English | EMBASE | ID: ppcovidwho-335597

ABSTRACT

Background: A rapid increase in incidence of the SARS-CoV-2 Omicron variant occurred in France in December 2021, while the Delta variant was prevailing since July 2021. We aimed to determine whether the risk of a severe hospital event following symptomatic SARS-CoV-2 infection differs for Omicron versus Delta. Methods: We conducted a retrospective cohort study to compare severe hospital events (admission to intensive care unit or death) between Omicron and Delta symptomatic cases matched according to week of virological diagnosis and age. The analysis was adjusted for age, sex, vaccination status, presence of comorbidities and region of residence, using Cox proportional hazards model. Findings: Between 06/12/2021-28/01/2022, 184 364 cases were included, of which 931 had a severe hospital event (822 Delta, 109 Omicron). The risk of severe event was lower among Omicron versus Delta cases;the difference in severity between the two variants decreased with age (aHR=0·11 95%CI: 0·07-0·17 among 40-64 years, aHR=0·51 95%CI: 0·26-1·01 among 80+ years). The risk of severe event increased with the presence of comorbidities (for very-high-risk comorbidity, aHR=4·18 95%CI: 2·88-6·06 among 40-64 years) and in males (aHR=2·29 95%CI: 1·83-2·86 among 40-64 years) and was higher in unvaccinated compared to primo-vaccinated (aHR=6·90 95%CI: 5·26-9·05 among 40-64 years). A booster dose reduced the risk of severe hospital event in 80+ years infected with Omicron (aHR=0·27;95%CI: 0·11-0·65). Interpretation: This study confirms the lower severity of Omicron compared to Delta. However, the difference in disease severity is less marked in the elderly.

11.
Embase; 2022.
Preprint in English | EMBASE | ID: ppcovidwho-335579

ABSTRACT

Background: The impact of chronic health conditions (CHC) on serostatus post-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is unknown. Methods: We assessed serostatus post-SARS-CoV-2 vaccination among fully vaccinated participants recruited between April 2021 through August 2021 in 18 years and older residents of Jefferson County, Kentucky, USA. Serostatus was determined by measuring SARS-CoV-2 Spike protein specific immunoglobulin (Ig) G (Spike IgG) antibodies via enzyme-linked immunoassay (ELISA) in peripheral blood samples. Results: Of the 5,178 fully vaccinated participants, 51 were seronegative and 5,127 were seropositive. Chronic kidney disease (CKD) (OR=13.49;95% CI: 4.88–37.3;P<0.0001) and autoimmune disease (OR=11.34;95% CI: 5.21–24.69;P<0.0001) showed highest association with negative serostatus in fully vaccinated participants. The absence of any CHC was strongly associated with positive serostatus (OR=0.37;95% CI: 0.19–0.73;P=0.003). The risk of negative serostatus increased in the presence of two CHCs (OR=2.82;95% CI: 1.14–7) to three or more CHCs (OR=4.52;95% CI: 1.68–12.14). Similarly, use of 2 or more CHC related medications was significantly associated with seronegative status (OR=6.08;95%: 2.01–18.35). Conclusions: Presence of any CHC, especially CKD or autoimmune disease, increased the likelihood of seronegative status among individuals who were fully vaccinated to SAR-CoV-2. This risk increased with a concurrent increase in number of comorbidities, especially with multiple medications. Absence of any CHC was protective and increased the likelihood of a positive serological response post-vaccination. These results will help develop appropriate guidelines for booster doses and targeted vaccination programs.

12.
International Journal of Environmental Research and Public Health ; 19(9):5365, 2022.
Article in English | ProQuest Central | ID: covidwho-1837776

ABSTRACT

Anxiety and depressive symptoms are common problems in adolescence that could be addressed by means of preventive interventions. Even though transdiagnostic cognitive behavior therapy (T-CBT) is potentially an ideal strategy to deal with anxiety and depression, it has rarely been used for preventive purposes. In addition, so far, no study has used internet-delivered T-CBT to prevent anxiety and depression in adolescents. This study aimed to examine the utility of AMTE, an internet-delivered T-CBT program, for the indicated prevention of anxiety and depression in adolescents. AMTE was applied to 30 adolescents (56.7% females, age range = 12–18 years, Mage = 14.00, SDage = 1.89) who showed subclinical symptoms of anxiety and/or depression. Participants were assessed at pre- and post-treatment and follow-up (3 months). We found that after the program, the symptoms of self-reported anxiety and depression, clinician-rated symptom severity, and self-reported and parent-reported severity of the main problems had significantly improved. In addition, there were significant improvements in anxiety sensitivity and emotional avoidance. Finally, we found high feasibility and acceptability of the program. AMTE is feasible and potentially effective for the indicated prevention of anxiety and depression as well as of clinical transdiagnostic factors, in adolescents.

13.
J Ayurveda Integr Med ; 13(1): 100476, 2022.
Article in English | MEDLINE | ID: covidwho-1838960

ABSTRACT

The COVID-19 pandemic is ravaging the world, leaving the mainstream medical system handicapped with no proven treatment at one end and the ambiguities regarding the efficacies of vaccines at the other. The elderly population is at greater risk in terms of complications and death. The use of complementary and alternative medicine (CAM) against COVID-19 has already been documented in countries like China with a national participation rate of 90%. In this regard, the practice of CAM especially Ayurveda is relevant in India. The current report is a case series of 64 elderly COVID-19 patients managed through a Non-Linear multi-modal Ayurveda Intervention (NLMAI) via online consultation. NLMAI is a combination of herbal and herbo-mineral drug interventions, lifestyle modifications, and psychological support done in 2 phases. The post-management analysis revealed a mean duration of 11 symptoms of COVID-19 assessed through survival function as 0.577 days [SE=0.39] with a CI of 95% [0.500-0.653] which was considerably low when compared to global statistics. Moreover, none of the cases advanced to complications or death. Hence, novel approaches like NLMAI can be utilized to counter the gravity of the COVID-19 after scientific validation.

14.
Indian Journal of Community Health ; 34(1):26-29, 2022.
Article in English | CAB Abstracts | ID: covidwho-1836661

ABSTRACT

Background: During the COVID- 19 pandemic in the first wave, infected patients age was range from 4 weeks to 90 years and those who have more age and with comorbidities are more susceptible to develop serious illness and have high mortality rates.

15.
Iranian Red Crescent Medical Journal ; 24(2), 2022.
Article in English | CAB Abstracts | ID: covidwho-1836514

ABSTRACT

Background: Coronavirus disease 2019 (COVID-19) has spread rapidly across the globe through coughing, sneezing, droplet inhalation, and contact. Objectives: The current study aimed to assess the impact of the fear of COVID-19 infection on functionality in women with breast cancer.

16.
Bioscientia Medicina ; 5(10):949-952, 2021.
Article in English | GIM | ID: covidwho-1836513

ABSTRACT

Background: Delirium is a common condition in geriatric patients. One of the trigger factors for this condition is an infection, such as COVID-19 infection. Elderly with COVID-19 show atypical symptoms such as delirium. Elderly patients with COVID-19 who present with delirium, either as a primary symptom or showing symptoms or signs, have a poor prognosis. This study were aimed to presents covid-19 elderly patient with comorbid delirium. Case presentation: A 77-year-old woman with disorientation for one day came to Emergency Department with her family. She had no history of headaches, blurred vision, or seizures. However, she had a fever, did not want to eat for three days, and had a purulent decubitus ulcer. The patient was diagnosed with acute delirium syndrome, confirmed COVID-19 with sepsis, malnutrition, hypercoagulation, grade III decubitus ulcer, suspected dementia, immobilization, total dependence. The patient admitted to the isolation ward. The patient had meropenem 500 mg every 12 hours, anticoagulants and favipiravir according to the dose and parenteral nutrition.

17.
Ukrainskyi Zhurnal Sertsevo-sudynnoi Khirurhii ; 2021(4):10-17, 2021.
Article in Ukrainian | Scopus | ID: covidwho-1836488

ABSTRACT

Every year we see an increase in the number of patients with indications for surgical treatment of coronary artery disease. In addition to the difficulties of the cardiac surgery process, no less important is the therapeutic support of patients, which in addition to cardiac subtleties requires guidance in concomitant nosologies. As the age of patients increases, there is a higher comorbidity which is associated with difficult management of patients, extensive prescription of drugs and higher cost of medical care. The aim. To analyze the current literature data on comorbidity in patients hospitalized for coronary artery bypass grafting. Results. According to the literature data, there is a high Charlson comorbidity index, in average 5.7 ± 1.7, in the baseline status of patients with coronary artery disease. High comorbidity index is known for its negative effect on the functioning of grafts in the long-term period after surgical myocardial revascularization. Among patients who underwent surgical revascularization of the myocardium, 22.8-46.9% had diabetes mellitus, 37.5% had obesity, 1.1% had rheumatoid arthritis and 10-12% suffered from chronic kidney disease. There is no statistical data on preoperative status of gastrointestinal tract, but the main complications and predictors of death were identified. Due to the increase in the occurrence of autoimmune diseases on the background of the COVID-19 pandemic, an increase in the number patients with connective tissue diseases in cardiac surgery is predicted, and perioperative management of such patients has its own characteristics and requires further in-depth study. Conclusions. Searching for comorbidity in cardiac surgery patients with coronary artery disease is an important component of their preoperative preparation and risk stratification. The influence of type 2 diabetes mellitus, obesity, autoimmune diseases, chronic kidney disease on the occurrence of postoperative complications and the result of surgical myocardial revascularization has been proven. SARS-CoV-2 infection in the surgical treatment of coronary artery disease is another challenge of today that requires further observation and research to help address prognosis, complications, and mortality. © 2021 The Authors.

18.
Journal of Epidemiology and Public Health ; 7(1):17-33, 2022.
Article in English | CAB Abstracts | ID: covidwho-1836439

ABSTRACT

Background: In DR Congo, South Kivu is among cities most affected by Covid 19 with its dense population and common mass movement. This study aimed at investigating the population behavior and practices during the spread period of Corona in South Kivu, East of Democratic Republic of Congo. Subjects dan Method: A cross-sectional analytical study was undertaken in South Kivu province and included 800 hundred individuals. The survey questionnaire was designed and comprised information on independent variables including socio-demographic and socioeconomic parameters, travel history of individuals, and person's history of COVID-19 comorbidity factors. These data were used to explain the dependent variable which was the population behavior and practices which was linked to the COVID-19 positivity or negativity. A rapid test of the COVID-19 antigen for people suspected of having cough and fever followed by RT-PCR tests was conducted. Statistical analyses were performed under R, version 3.5.1.

19.
China Tropical Medicine ; 22(2):143-147, 2022.
Article in Chinese | GIM | ID: covidwho-1835962

ABSTRACT

Objective: The aim of this study is to investigate the clinical and laboratory features in confirmed COVID-19 patients without specific anti-SARS-CoV-2 antibody,it is important to interpret SARS-CoV-2 antibody test results correctly and provide effective management for COVID-19 patients without specific anti-SARS-CoV-2 antibody.

20.
Chinese General Practice ; 25(11):1294-1304 and 1308, 2022.
Article in Chinese | Scopus | ID: covidwho-1835842

ABSTRACT

Global initiative for chronic obstructive lung disease (GOLD) 2022 report was released on November 15, 2021. In general, chronic obstructive pulmonary disease (COPD) diagnosis, assessment and individualized therapy are the same as GOLD 2021, with corresponding content added in ten aspects. The article introduces and interprets the new content. Copyright © 2022 by the Chinese General Practice.

SELECTION OF CITATIONS
SEARCH DETAIL